stockportfolio.pro
Stocks / HTFL vs SUPN
HTFL vs SUPN
Heartflow, Inc. and Supernus Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Heartflow, Inc. (HTFL) | Supernus Pharmaceuticals, Inc. (SUPN) | |
|---|---|---|
| Market cap | $2.7B | $2.6B |
| Revenue (latest FY) | $176.03M | $718.95M |
| Net income (latest FY) | $-116.79M | $-38.55M |
| Revenue growth (5y CAGR) | 42.1% | 6.7% |
| Net margin | -66.3% | -5.4% |
| Return on equity | -38.8% | -3.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HTFL — free Open SUPN — freeFrequently asked questions
Which is bigger, HTFL or SUPN?
Heartflow, Inc. is larger by market capitalization — $2.7B versus $2.6B.
Which grows faster, HTFL or SUPN?
Over the last five fiscal years, Heartflow, Inc. grew revenue faster — 42.1%/yr versus 6.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.